StockData

Kazia Therapeutics vs Lisata Therapeutics

KZIA and LSTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KZIA and LSTA compare

Lisata Therapeutics grew revenue faster over the last twelve months (−90.7% versus −98.2% for Kazia Therapeutics).

Lisata Therapeutics keeps more of each dollar of sales as profit, with a net margin of −14621% compared with −49291% at Kazia Therapeutics.

Lisata Therapeutics scores higher on the StockData Score (6 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKZIALSTA
Size and price
Market cap–$9.4M
Share price$5.31$1.04
Change, 1 year−15.3%−50.9%
Change, 5 years−98.9%−92.9%
Beta (5Y)4.08−1.59
Employees1421
StockData Score
Total score16 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score15 (better)
Dividend score00
Valuation
P/S–93.7×
P/B–1.1×
FCF yield–−131%
Growth
Revenue growth (TTM)−98.2%−90.7% (better)
Profitability
Operating margin–−16427%
Net margin−49291%−14621% (better)
FCF margin–−12323%
Return on equity–−99.9%
Return on invested capital–−1645%
Financial health
Debt / equity–0.00
Current ratio2.873.69 (better)
Altman Z-score–−74.81
Piotroski F-score2 (better)1
Dividends and buybacks
Buyback yield–−6.3%
Shareholder yield–−6.3%
Ownership
Held by institutions0.45%12.1%
Held by insiders0.29%11.6%
Superinvestors holding1–
Short interest, % of float–0.43%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.